Eledon Pharmaceuticals has filed a notice of an exempt offering of securities to raise $35,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Eledon Pharmaceuticals is raising $35,000,000.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Paul Little played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. Our lead program, AT-1501, is a potential best-in-class humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.
To learn more about Eledon Pharmaceuticals, visit http://eledon.com/
Contact:
Paul Little, Chief Financial Officer
949-238-8090
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.